I played a VC firm's risk game about fake drugs. It revealed unsettling truths about AI and attention.

On a bustling Tuesday evening in Manhattan, venture capital firm Lux Capital hosted an intriguing 'risk game' at the upscale Ned hotel, where journalists, investors, and academics came together to explore the murky waters of pharmaceutical innovation and public perception. This elaborate thought experiment, designed to mimic real-world dilemmas, was the latest installment in Lux's series of immersive games that challenge participants to navigate complex scenarios inspired by actual trends in the industry. Participants were thrust into a fictional scenario involving three experimental drugs, each claiming to enhance cognitive function. As I donned my nametag identifying me as a health policy advisor to a Republican senator from Ohio, my goal became clear: advocate for the approval of two American drugs by the FDA and undermine a competing European alternative. The atmosphere buzzed with tension, reminiscent of the rapid rise of popular GLP-1 drugs like Ozempic. Among the attendees was Justin Bokmeyer, the director of basketball operations for the Brooklyn Nets, who had extensive experience in similar games. The competitive spirit ignited quickly, with players trading information cards to garner attention cards that would aid in promoting their political agenda. However, in a crowded room filled with nearly 40 participants, information quickly became a hot commodity. I found myself holding crucial data about my drugs while trying unsuccessfully to negotiate for attention with influencers reluctant to take risks without guaranteed virality. Amidst the chaos, a player masquerading as a neuroethics professor interrupted, warning that the drugs in question were being marketed by 'evil corporations' aiming to enrich the elite at the expense of the masses. Fueled by a sense of urgency, I countered that his stance threatened the very fabric of American innovation. The evening revealed the unpredictable nature of truth when science, politics, and economics intersect in the attention-driven landscape. Laurence Pevsner, the Lux research partner behind this game, shared that the scenario was influenced by various real-life issues, including misinformation surrounding mRNA vaccines and the polarizing nature of discussions about cryptocurrency and NFTs. However, the specter of artificial intelligence loomed largest over the proceedings, prompting Pevsner to note that the game's themes mirrored the dual potential of AI as both a tool for enhancement and a source of conflict. This particular game, aptly titled "Gray Matter: Selling Science in the Age of Attention," had been meticulously crafted over several months, with character roles ranging from NIH executives to social media personalities. Each character came with a rich backstory; my own was rooted in a childhood experience that shaped my views on healthcare. Lux Capital's approach to these games, which are free to join and available for public use, is to foster meaningful connections among participants, potentially sparking new ideas or collaborations. As the game reached its climax, I rushed to present my findings to influence the FDA's decision, but ultimately, my character's mission faltered. The conclusion revealed that while the American drugs held genuine cognitive benefits, the European alternative was merely a well-marketed placebo. This ironic twist underscored the evening's central theme: in today's world, where misinformation can spread like wildfire, the perceived truth often outweighs factual accuracy. As the game wrapped up, participants expressed interest in bringing these thought-provoking scenarios to their organizations, eager to engage in deeper discussions about the complexities of the modern information landscape. As Crichton aptly stated, the goal is not to provide answers but to inspire better questions amid the chaos of our attention-driven society.